HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

8/21/24 8:05:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HRMY alert in real time by email

PLYMOUTH MEETING, Pa., Aug. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:

Wells Fargo 2024 Healthcare Conference

Location: Boston
Fireside Chat: Thursday, September 5, 2024, at 9:30 a.m. ET

2024 Cantor Global Healthcare Conference

Location: New York City
Fireside Chat: Tuesday, September 17, 2024, at 3:05 p.m. ET

A webcast of the fireside chats will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:

Brennan Doyle

484-539-9700

[email protected]

Harmony Biosciences Media Contact:

Cate McCanless

202-641-6086

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-upcoming-investor-conferences-302225692.html

SOURCE Harmony Biosciences

Get the next $HRMY alert in real time by email

Recent Analyst Ratings for

$HRMY

Date	Price Target	Rating	Analyst
10/10/2024		Outperform	Raymond James
9/10/2024	$56.00	Buy	UBS
6/21/2024	$48.00	Buy	Citigroup
1/2/2024	$30.00	Neutral → Underperform	BofA Securities
9/25/2023	$40.00 → $31.00	Neutral → Sell	Goldman
9/7/2023	$59.00	Buy	Berenberg
4/20/2023	$35.00	Neutral	BofA Securities
10/14/2022	$57.00 → $61.00	Hold → Buy	Jefferies

More analyst ratings

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Chat with this insight

Recent Analyst Ratings for $HRMY

$HRMY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on Harmony Biosciences

UBS initiated coverage on Harmony Biosciences with a new price target

Citigroup initiated coverage on Harmony Biosciences with a new price target

$HRMY SEC Filings

Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 424B7 filed by Harmony Biosciences Holdings Inc.

SEC Form 424B7 filed by Harmony Biosciences Holdings Inc.

$HRMY Press Releases

Fastest customizable press release news feed in the world

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

Axonis Therapeutics Announces $115 Million Series A Financing

$HRMY Market Insights

Live Market Insights

$HRMY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$HRMY Financials

Live finance-specific insights

FDA Confirms Favorable Benefit-Risk Profile Of WAKIX; Harmony Biosciences Plans To Launch At Least One New Product Or Indication Annually Over Next Five Years; Denial Of Citizen Petition Confirms WAKIX's Safety And Efficacy For EDS And Cataplexy In Adults With Narcolepsy

Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target

Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target

Large owner Valor Iv Pharma Holdings, Llc sold $139,391,500 worth of shares (4,600,000 units at $30.30), decreasing direct ownership by 41% to 6,618,033 units (SEC Form 4)

Large owner Marshman Fund Trust Ii sold $139,391,500 worth of shares (4,600,000 units at $30.30), decreasing direct ownership by 43% to 6,051,120 units (SEC Form 4)

CHIEF COMMERCIAL OFFICER Dierks Jeffrey sold $870,018 worth of shares (21,496 units at $40.47) and exercised 21,496 shares at a strike of $24.00 (SEC Form 4)

HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS

HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024

Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028

$HRMY Leadership Updates

Live Leadership Updates

HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors

John C. Jacobs, President and CEO of Harmony Biosciences, Joins Life Sciences Pennsylvania Board of Directors

$HRMY Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

Recent Analyst Ratings for
$HRMY

$HRMY
Analyst Ratings

$HRMY
SEC Filings

$HRMY
Press Releases

$HRMY
Market Insights

$HRMY
Insider Trading

$HRMY
Financials

$HRMY
Leadership Updates

$HRMY
Large Ownership Changes